<DOC>
	<DOCNO>NCT00712296</DOCNO>
	<brief_summary>The purpose study determine efficacy anti-asthma herbal medicine intervention ( ASHMI ) adult asthmatic</brief_summary>
	<brief_title>Effectiveness Chinese Herbal Therapy Asthma</brief_title>
	<detailed_description>Asthma major public health problem worldwide , particularly westernized society continue increase prevalence past two decade . Inhaled corticosteroid become first-line treatment persistent asthma even though side effect report . New asthma medication , include leukotriene inhibitor anti-IgE , show limited benefit . Patients increasingly turn complementary alternative medicine ( CAM ) treatment asthma , despite uncertainty benefit due lack well-controlled scientific study . We develop Chinese herbal formula compose 3 herb call ASHMI . It previously show murine study ASHMI ( formula contain Ling Zhi , Ku Shen Gan Cao ) therapeutic effect major pathogenic mechanism asthma-airway hyperreactivity , pulmonary inflammation , airway remodel , well down-regulating TH2 response . A subsequent study 91 asthmatic patient Weifang , China find ASHMI safe effective alternative prednisone treat asthma exhibit beneficial effect TH1 TH2 balance . Additionally , Phase I study conduct United States show good tolerability ASHMI . Based preliminary study , hypothesize ASHMI safe medication patient asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female subject age 18 55 otherwise good health determine medical history physical examination History asthma document physician least 6 month Females childbearing potential must sexually inactive take effective birth control measure , deem appropriate investigator , duration study The subject agree participate study Subjects must one following : one asthmarelated unscheduled visit Emergency Department clinic past 12 month One overnight hospitalization past 12 month Disturbed sleep twice past month Asthma symptoms ≥8 time past month use β2agonist ≥8 time past month two short course ( 37 day ) oral corticosteroid last 12 month FEV1 &lt; 80 % predict AND Use inhale corticosteroid ( ICS ) least 1 month prior enrollment Acute illness ( cold , flu , etc . ) within two week screen visit Any history systemic disease investigator 's opinion would preclude subject participate study , include hepatitis virus infection History chronic obstructive lung disease , emphysema , chronic respiratory condition Abnormal hepatic function ( ALT/AST bilirubin &gt; 1.25 x upper limit normal ) Abnormal bone marrow function ( WBC &lt; 4 x 103/mm3 ; platelet &lt; 100 x 103/mm3 ; Hgb &lt; 11 g/dl ) Abnormal renal function ( BUN creatinine &gt; 1.25 x upper limit normal ) Clinically significant abnormal electrocardiogram FEV1 &lt; 50 % predicted Participation another experimental therapy study within 30 day study History alcohol drug abuse Pregnant lactate female subject . Females childbearing potential need negative serum pregnancy test screening consider study Subjects receive treatment Omalizumab immunotherapy asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>alternative medicine</keyword>
	<keyword>complementary medicine</keyword>
	<keyword>herbal therapy</keyword>
</DOC>